Skin Biopsy Tau Synuclein

Introduction

flowchart TD
    Skin["Skin"] -->|"expressed in"| Corticosterone["Corticosterone"]
    SKIN["SKIN"] -->|"expresses"| IL6["IL6"]
    style SKIN fill:#4fc3f7,stroke:#333,color:#000

Skin biopsy has emerged as a valuable minimally invasive diagnostic tool for detecting pathological protein aggregates in neurodegenerative diseases. Unlike cerebrospinal fluid (CSF) collection, which requires lumbar puncture, or neuroimaging, which is expensive and not always available, skin biopsy offers a relatively simple outpatient procedure with growing clinical utility. This page covers the use of skin biopsy for detecting phosphorylated alpha-synuclein (p-syn) and tau protein, with emphasis on its role in differentiating atypical parkinsonian disorders such as corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), Parkinson’s disease (PD), and multiple system atrophy (MSA)[@gibbons2018].

Background

Pathological Proteins in Neurodegeneration

The hallmark pathological proteins in neurodegenerative diseases include:

Alpha-synuclein: Forms Lewy bodies in PD and MSA, and neuronal cytoplasmic inclusions in PD and DLB
Tau: Forms neurofibrillary tangles in Alzheimer’s disease, and 4R tau inclusions in PSP and corticobasal degeneration (CBD)
TDP-43: Found in ALS and frontotemporal dementia

Detecting these proteins outside the central nervous system has diagnostic significance because their presence or absence can help distinguish between different neurodegenerative disorders[@doppler2015].

Rationale for Skin Biopsy

The skin is innervated by small nerve fibers that can accumulate pathological proteins through transneural transport or via the peripheral nervous system. Studies have demonstrated that phosphorylated alpha-synuclein can be detected in skin nerve fibers, particularly in autonomic nerve endings. Similarly, tau protein accumulation has been reported in skin fibroblasts and nerve endings in some tauopathies[@zange2021].

Technique

Sample Collection

The standard skin biopsy protocol for neurodegenerative disease assessment involves:

Site Selection: Typically three-millimeter punch biopsies are taken from:
- Posterior cervical region (neck, near the hairline) — rich in autonomic nerve endings
- Distal leg (below the knee) — sural nerve territory
- Sometimes additional sites are included
Procedure:
- Local anesthesia (1-2% lidocaine) is administered
- A 3mm punch biopsy is performed
- The sample is immediately placed in formalin or a specific fixation solution
- Multiple sections are prepared for immunohistochemistry
Number of Biopsies: Most protocols use 2-3 biopsy sites, with at least one from a site with high autonomic innervation[@adler2020].

Processing and Analysis

The tissue samples undergo:

Immunohistochemistry (IHC): Staining with antibodies specific for phosphorylated alpha-synuclein (e.g., pSer129 alpha-synuclein)
Immunofluorescence: Multiple fluorescence-labeled antibodies allow for co-localization studies
Western Blot: For quantitative analysis of protein aggregates
Confocal Microscopy: For three-dimensional visualization of protein deposits

Alpha-Synuclein Detection

Clinical Significance

Phosphorylated alpha-synuclein at Ser129 (p-syn) is the major pathological form found in Lewy bodies and other alpha-synucleinopathies:

Positive p-syn: Indicates an alpha-synucleinopathy — PD, MSA, or dementia with Lewy bodies (DLB)
Negative p-syn: Suggests a tauopathy (PSP, CBD) or other non-synuclein pathology

Sensitivity and Specificity

Disease	Sensitivity	Specificity (vs. PSP/CBD)
PD	70-90%	85-95%
MSA	80-95%	85-95%
DLB	75-90%	85-95%
PSP	<5%	N/A
CBD/CBS	<5%	N/A

Data from multiple studies[@donadio2019][@kim2021]

Interpretation Guidelines

Positive Result (p-syn detected):

Supports diagnosis of an alpha-synucleinopathy (PD, MSA, DLB)
Does not definitively distinguish between PD, MSA, and DLB
Higher sensitivity in clinically established disease

Negative Result (p-syn not detected):

Does not rule out alpha-synucleinopathy entirely (sensitivity is not 100%)
More consistent with tauopathy (PSP, CBD) or other non-synuclein disorder
Consider repeat testing if clinical suspicion remains high

Tau Protein Detection

Current State

Tau detection in skin biopsies is less well-established than alpha-synuclein detection but shows promise:

Total tau: Can be detected but is less disease-specific
Phosphorylated tau (p-tau): Research is ongoing to develop reliable detection methods
4R tau: Specific antibodies are being validated for PSP and CBD detection[@liu2021]

Research Applications

Skin biopsy-based tau detection is primarily used in research settings. Clinical applications are still emerging. Some studies have reported:

Elevated total tau in skin fibroblasts from AD patients
Detection of hyperphosphorylated tau in skin nerve fibers in AD
Ongoing work to develop clinically validated tau detection assays

Clinical Utility

Differential Diagnosis

Skin biopsy is particularly useful in the following clinical scenarios:

Atypical Parkinsonism: When differentiating PD/MSA from PSP/CBS
- Positive p-syn → supports PD/MSA
- Negative p-syn → suggests PSP/CBS
Dementia Workup: When determining whether dementia is due to Lewy body disease or other causes
- Positive p-syn → supports DLB
- Negative → consider AD, FTD, or other causes
Prodromal Detection: Some studies suggest p-syn can be detected before clinical diagnosis in PD[@wang2022]

Advantages

Minimally invasive: Simple outpatient procedure
Low risk: Similar to skin biopsy for other indications
Widely available: Can be performed in most dermatology or neurology offices
Relatively inexpensive: Compared to PET imaging
Repeatable: Allows for longitudinal monitoring

Limitations

Not definitive: Positive/negative results are probabilistic, not diagnostic
Variable sensitivity: Depends on disease stage and biopsy technique
Limited availability: Not all laboratories perform these specialized assays
Interpretation expertise: Requires experienced neuropathologists

Comparison with Other Diagnostic Methods

Method	Invasiveness	Cost	Sensitivity (PD)	Sensitivity (PSP/CBS)
Skin Biopsy	Low (minor)	$$	70-90%	<5%
CSF Biomarkers	Moderate (LP)	$$	Variable	Moderate
DAT Scan	Moderate (radiation)	$$$	High	Variable
Tau PET	High (radiation)	$$$$$	Low	Moderate
Clinical Exam	None	$	Variable	Variable

Clinical Recommendations

When to Consider Skin Biopsy

Atypical parkinsonian presentations where differentiating alpha-synucleinopathies from tauopathies would affect management
Unclear diagnosis between PD, MSA, and PSP/CBS
Research participation or clinical trials requiring biomarker confirmation
Patient preference when more invasive tests are not acceptable

Interpretation in Context

Skin biopsy results should always be interpreted in the context of:

Clinical history and examination findings
Other diagnostic test results
Disease duration and stage
Treatment response

Skin Biopsy for Tau and Alpha-Synuclein